Moleculin Biotech, Inc.

Research Moleculin Biotech, Inc. (0K2H) with Bullrun company financials, valuation charts, model signals, and historical stock context.

Key Metrics

• Ticker0K2H
• ExchangeLSE
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases.

Frequently asked questions

What does Moleculin Biotech, Inc. do?

Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses.